PUBLIC COMPANY
save$SMMTSummit Therapeutics Inc.
$SMMT9.9500-5.87%Miami, FL, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- phase3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- phase3Phase III Study of AK112 for NSCLC Patients
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- phase3Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
🐶 Hiring Signal
News
- This week in charts: Biotech investors’ China bets are already paying offThis year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.biopharma_dive · 2d ago
- FDA’s search for a new leader, and China’s largest drugmakersThis week on "The Readout LOUD" podcast: the FDA is again searching for a new leader and a closely tracked lung cancer drug suffers an agency rejection.stat · 2d ago
- STAT+: FDA discloses reasons for rejecting Summit drugThe FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:stat · 4d ago
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 4d ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetySummit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.biospace · 4d ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 4d ago
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 4d ago
- FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity riskThe FDA signaled new interest in the safety of Summit Therapeutics and Akeso’s cancer drug ivonescimab, saying that it turned down the treatment’s use in a form of lung cancer in part ...endpoints · 4d ago
- FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival missThe FDA’s rejection of Summit Therapeutics’ closely watched PD-1xVEGF bispecific ivonescimab extends beyond its previously reported failure to show a statistically significant overall survival bene…fiercebiotech · 5d ago
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drugThe FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.biopharma_dive · 6d ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that